Cascade Prodrug Closes Series A Financing

EUGENE, Ore. – (June 29, 2012) – Cascade Prodrug, Inc. closed on a preferred series A financing in excess of $1.4mm. The round was led by The Oregon Angel Fund. The proceeds will be used to further develop in preclinical trials the company’s novel prodrug technology platform for its lead compounds. “We are gratified by confidence shown by investors funding the further development of these exciting prodrugs,” commented Allan Cochrane, Cascade’s President and Cofounder.

About CascadeProdrug

No Comments

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Powered by WishList Member - Membership Software